Shrink Tech sold to Shrink Nanotech

4 June 2009

Shrink Technologies, a California, USA-based company, has agreed to be acquired in a stock-for-stock transaction by Shrink Nanotechnologies.  The transaction closed on May 29 and, as a result, it has become a  wholly-owned subsidiary of the latter, a Delaware corporation. The  transaction purchase price was just under $9.0 million and called for  Shrink to issue 8,888,888 common shares, 50 series C preferred stock and  to add one new person to the Shrink board of directors. The closing  price of Shrink's stock on the date of the acquisition was $1.01 per  share. Shrink has applied for a new stock market symbol with FINRA and  expects to trade under a new symbol in the coming weeks.

Commenting on the acquisition, Shrink chief executive Mark Baum stated:  "we are pleased to have concluded the transaction to acquire Shrink  Technologies, a company with a very promising portfolio of licensed  technologies which we believe will be impactful in a number of  fast-growing, multi-billion dollar markets. We also welcome to Shrink, a  team of world-class scientists and technology innovators from some of  our nation's most prestigious academic institutions."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight